Brokerages expect Savara Inc (NASDAQ:SVRA) to post earnings per share of ($0.08) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Savara’s earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.12). Savara posted earnings per share of ($0.27) during the same quarter last year, which suggests a positive year-over-year growth rate of 70.4%. The company is expected to announce its next earnings results on Thursday, May 6th.
According to Zacks, analysts expect that Savara will report full-year earnings of ($0.40) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.27). For the next year, analysts anticipate that the firm will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.49) to ($0.24). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Savara.
A number of analysts have issued reports on the stock. Zacks Investment Research cut shares of Savara from a “buy” rating to a “hold” rating in a research note on Saturday. HC Wainwright reduced their target price on shares of Savara from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 15th. Oppenheimer assumed coverage on shares of Savara in a research note on Monday, March 22nd. They issued an “outperform” rating and a $4.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of Savara in a research note on Monday, March 22nd. They issued an “overweight” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.06.
In related news, CEO Matthew Pauls bought 24,100 shares of the company’s stock in a transaction that occurred on Monday, March 22nd. The shares were acquired at an average price of $2.07 per share, with a total value of $49,887.00. Following the completion of the transaction, the chief executive officer now owns 280,722 shares of the company’s stock, valued at approximately $581,094.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph S. Mccracken bought 68,965 shares of the company’s stock in a transaction that occurred on Monday, March 15th. The shares were bought at an average cost of $1.45 per share, for a total transaction of $99,999.25. Following the transaction, the director now directly owns 168,337 shares of the company’s stock, valued at approximately $244,088.65. The disclosure for this purchase can be found here. In the last three months, insiders bought 135,558 shares of company stock worth $219,824. Insiders own 4.77% of the company’s stock.
A number of hedge funds have recently made changes to their positions in SVRA. BlackRock Inc. increased its holdings in Savara by 6.3% in the 4th quarter. BlackRock Inc. now owns 3,010,030 shares of the company’s stock valued at $3,461,000 after buying an additional 178,861 shares during the period. Renaissance Technologies LLC increased its holdings in Savara by 2.6% in the 4th quarter. Renaissance Technologies LLC now owns 399,900 shares of the company’s stock valued at $460,000 after buying an additional 10,200 shares during the period. JPMorgan Chase & Co. increased its holdings in Savara by 698.8% in the 4th quarter. JPMorgan Chase & Co. now owns 143,729 shares of the company’s stock valued at $166,000 after buying an additional 125,737 shares during the period. Brown Advisory Inc. increased its holdings in Savara by 23.1% in the 4th quarter. Brown Advisory Inc. now owns 111,044 shares of the company’s stock valued at $128,000 after buying an additional 20,854 shares during the period. Finally, Rhumbline Advisers increased its holdings in Savara by 16.7% in the 4th quarter. Rhumbline Advisers now owns 70,848 shares of the company’s stock valued at $81,000 after buying an additional 10,135 shares during the period. 40.66% of the stock is currently owned by institutional investors and hedge funds.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More: What is a Fibonacci Channel?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.